JPRN-jRCT2043200002已完成1 期
Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
When ADR-001 was administered once or twice to patients with IgA nephropathy resistant to existing therapies, safety was confirmed and symptoms were partially improved.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) IgA nephropathy diagnosed by renal biopsy.
- •2) Meet any of the following criteria.
- •i. Urinary protein at screening is 0.5 g / gCr or more and eGFR is 60 mL / min / 1.73m^2 or more even if corticosteroids are used for 6 months or more before screening.
- •ii. Urine protein of 1.0 g / gCr or more and eGFR of 30 mL / min / 1.73 m^2 or more and less than 60 mL / min / 1.73 m^2 at screening even if corticosteroids are used for 6 months or more before screening.
- •iii. Urine protein of 0.5 g / gCr or more and less than 1.0 g / gCr at screening and eGFR of 20 mL / min / 1.73m^2 or more and 60 mL / min / 1.73m^2 or urine protein of 1.0 g / gCr or more at screening And eGFR is 20 mL / min / 1.73m^2 or more and less than 30 mL / min / 1.73m^2.
- •3) Over 20 years old.
- •4) Able to provide informed consent.
- •However, in the first cohort, only 2) -i is applied in the selection criteria 2), and in the second cohort, 2) -i, ii, and iii are applied.
排除标准
- •1) Nephropathy other than IgA nephropathy, and primary and secondary nephrotic syndrome.
- •2) Start or increase drug therapy for IgA nephropathy with corticosteroids, immunosuppressants, renin angiotensin system (RAS ) inhibitors, antiplatelet drugs, anticoagulants (warfarin), and n-3 fatty acids (fish oil) within 3 months . Palatal tonsillectomy within 6 months.
- •3) Treatment with other cells.
- •4) Participated within 3 months or participating in other clinical trials .
- •5) Penal transplantation within 3 years or scheduled.
- •6) Diabetics not well controlled.
- •7) Malignant neoplasm or history of malignant neoplasm within 5 years, or judged possibility of malignant tumor.
- •8) Suspected of active infection.
- •9) Positive for hepatitis B (HB), hepatitis C virus (HCV),human Immunodeficiency virus (HIV), human T-cell leukemia virus 1 (HTLV-1) or syphilis.
- •10) History of severe hypersensitivity or anaphylactic reaction.
- •11) Allergic to penicillin antibiotics, aminoglycoside antibiotics or dimethyl sulfoxide (DMSO).
- •12) Serious complications not related to IgA nephropathy.
- •13) Bleeding or may bleed, shallow days after surgery or trauma to the central nervous system, history of hypersensitivity to components of heparin preparations, history of heparin-induced thrombocytopenia Previous patient.
- •14) During pregnancy, lactation, may be pregnant or both men and women who do not agree to give birth control under the guidance of the investigator or investigator during the study period.
研究者
相似试验
已完成
1 期
The Clinical Trial of ADR-001 for IgA NephropathyGlomerulonephritis , IGANCT04342325Nagoya University9
招募中
2 期
A Phase 2 Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infectioPatients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT2053210023Okawa Sumito20
Unknown
4 期
Rituximab in Recurrent IgA NephropathyRecurrent IgA NephropathyNCT02571842Chulalongkorn University30
招募中
4 期
Dapagliflozin treatment in IgA nephropathy patientsIgA nephropathyJPRN-jRCT1031220369Tomohito Gohda150
Unknown
不适用
ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCTGlomerulonephritis, IGANCT00378443Peking University